The other side of technology: Risk of overdiagnosis of breast cancer with mammography screening

Future Oncology

Volumn 5, Issue 4, 2009, Pages 481-491

  Puliti, Donella ^a   Paci, Eugenio ^a  

^a ISPO Cancer Prevention and Research Institute   (Italy)

Author keywords

Breast cancer; Cumulative incidence method; Overdiagnosis; Overtreatment; Service screening

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HUMAN; ITALY; MAMMOGRAPHY; MASTECTOMY; METHODOLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SWEDEN; BREAST TUMOR; CANCER DIAGNOSIS; FEMALE; MASS SCREENING; RADIOGRAPHY; RISK;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 67651230916     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.25     Document Type: Review

References (44)

1. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ: Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-1998: comparison of observed with predicted mortality. BMJ 321(7262), 665-669 (2000).
2. Swedish Organised Service Screening Evaluation Group: Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol. Biomarkers Prev. 15(1), 45-51 (2006).
3. Otten JD, Broeders MJ, Fracheboud J et al.: Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006. Int. J. Cancer 123(8), 1929-1934 (2008).
4. Puliti D, Miccinesi G, Collina N et al.: Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction. Br. J. Cancer 99, 423-427 (2008).
5. von Karsa L, Anttila A, Ronco G et al.: Cancer screening in the European Union. Report on the implementation of the council recommendation on cancer screening - First Report. IARC Press, Luxembourg, 16-18 (2008).
6. Perry N, Broeders M, de Wolf C (Eds): European guidelines for quality assurance in breast cancer screening and diagnosis. Office for official Publications of the European Commission, Luxembourg (2006).
7. Morrison AS: Screening in chronic disease. Monographs in epidemiology and biostatistics. Oxford University Press, NY, USA, 7 (1985).
8. Parkin DM, Moss SM: Lung cancer screening: improved survival but no reduction in deaths--the role of 'verdiagnosis'. Cancer 89, 2369-2376 (2000).
9. Zappa M, Ciatto S, Bonardi R, Mazzotta A: Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann. Oncol. 9, 1297-1300 (1998).
10. International Agency for Research on Cancer Expert Group: Breast cancer screening. In: IARC Handbooks of Cancer Prevention. IARC, Lyon, France, 7, 145 (2002).
11. Duffy SW, Agbaje O, Tabar L et al.: Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Br. Cancer Res. 7(6), 258-265 (2005).
12. Paci E, Warwick J, Falini P, Duffy SW: Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J. Med. Screen. 11(1), 23-27 (2004).
13. Paci E, Duffy S: Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res. 7(6), 266-270 (2005).
14. Duffy SW, McCann J, Godward S, Gabe R, Warwick J: Some issues in screening for breast and other cancers. J. Med. Screen. 13(Suppl. 1), S28-S34 (2006).
15. Zorzi M, Puliti D, Vettorazzi M et al.; IMPACT Working Group: Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997-2001). Br. J. Cancer 95(9), 1265-1268 (2006).
16. Cardoso F, Van't Veer L, Rutgers E et al.: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008).
17. Moss S: Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 7(5), 230-234 (2005).
18. Zackrisson S, Andersson I, Janzon L et al.: Rate of overdiagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 332, 689-692 (2006).
19. The Breast Screening Frequency Trial Group: The frequency of breast cancer screening: results from the UKCCCR randomized trial. Eur. J. Cancer 38, 1458-1464 (2002).
20. Zappa M, Falini P, Bonardi R et al.: Monitoring interval cancers in mammographic screening: the Florence District programme experience. Breast 11(4), 301-305 (2002).
21. Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Br. Med. J. 328, 921-924 (2004).
22. Zahl PH, Maehlen J, Welch HG: The natural history of invasive breast cancers detected by screening mammography. Arch. Intern. Med. 168(21), 2311-2316 (2008).
23. Paci E, Puliti D, Zappa M: Screening and breast cancer: Florentine data. Author reply. Arch. Intern. Med. (2009) (In press).
24. Olsen AH, Jensen A, Njor SH et al.: Breast cancer incidence after the start of mammography screening in Denmark. Br. J. Cancer 88, 362-365 (2003).
25. McCann J, Treasure P, Duffy S: Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. J. Med. Screen 11(3), 117-125 (2004).
26. Paci E, Warwick J, Falini P, Duffy SW: Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J. Med. Screen 11(1), 23-27 (2004).
27. Paci E, Miccinesi G, Puliti D et al.: Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res. 8(6), R68 (2006).
28. Jonsson H, Johansson R, Lenner P: Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int. J. Cancer 117(5), 842-847 (2005).
29. Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH: Complexities in the estimation of overdiagnosis in breast cancer screening. Br. J. Cancer 99(7), 1176-1178 (2008).
30. Shen Y, Yang Y, Inoue LY, et al.: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J. Natl Cancer Inst. 97, 1195-1203 (2005).
31. Wishart GC, Greenberg DC, Britton PD et al.: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br. J. Cancer 98, 1741-1744 (2008).
32. Paci E, Ponti A, Crocetti E, et al.: Re: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J. Natl Cancer Inst. 97, 1853-1854 (2005).
33. Paci E, Coviello E, Miccinesi G, Puliti D et al.: Evaluation of service screening impact in Italy: the contribution of hazard analysis. Eur. J. Cancer 44, 858-865 (2008).
34. Berry DA: The screening mammography paradox: better when found, perhaps better not to find. Editorial. Br. J. Cancer 98, 1729-1730 (2008).
35. Ernster VL, Ballard-Barbash R, Barlow WE et al.: Model of outcomes of screening mammography: spontaneous regression of breast cancer may not be uncommon. BMJ 331(7512), 350 (2005).
36. Zahl PH, Maehlen J: Model of outcomes of screening mammography: spontaneous regression of breast cancer may not be uncommon. BMJ 331(7512), 350 (2005).
37. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur. J. Cancer 39, 1746-1754 (2003).
38. Duffy SW, Tabar L, Vitak B et al.: The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur. J. Cancer 39, 1755-1760 (2003).
39. Draisma G, Boer R, Otto SJ et al.: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J. Natl Cancer Inst. 95(12), 868-878 (2003).
40. Etzioni R, Penson DF, Legler JM et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl Cancer Inst. 94(13), 981-990 (2002).
41. Welch HG, Schwartz LM, Woloshin S: Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ 332, 227 (2006).
42. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L: Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 8(12), 1129-1138 (2007).
43. Shen Y, Zelen M: Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J. Clin. Oncol. 19, 3490-3499 (2001).
44. Walter SD, Day NE: Estimation of the duration of a preclinical disease state using screening data. Am. J. Epidemiol. 118, 865-886 (1983).